Deep 6 AI

Deep 6 AI provides an advanced software platform that uses artificial intelligence and natural language processing to mine structured and unstructured clinical data from electronic medical records. This enables real-time precision matching of patients to clinical trials, accelerating recruitment timelines for sponsors and sites. The company’s technology has demonstrated significant improvements in patient identification rates for studies at major academic centers. It does not conduct its own drug or device trials but supports the industry by improving trial feasibility assessment, site selection, cohort building, diversity in enrollment, and real-world evidence generation. In March 2025 it was acquired by Tempus. No direct clinical results as a therapeutic developer.